Nexalin Technology, in partnership with the University of California, San Diego, has unveiled its innovative AI-powered virtual clinic platform, NeuroCare. This launch signifies a major stride in expanding healthcare accessibility, mitigating expenses, and fostering sustained patient engagement for individuals grappling with various brain-related ailments.
The collaborative effort extends Nexalin's ongoing research endeavors with UC San Diego, where clinical trials for Nexalin's non-invasive Deep Intracranial Frequency Stimulation (DIFS) are already underway. The NeuroCare digital platform seamlessly integrates with Nexalin's latest Gen-3 HALO headset, facilitating enhanced DIFS delivery within the comfort of patients' homes. This clinical trial also marks the official introduction of the Gen-3 HALO headset, which is meticulously managed and monitored via the Nexalin NeuroCare virtual clinic throughout the treatment process.
Through the NeuroCare platform, individuals suffering from conditions such as Alzheimer's/dementia, mood disorders like depression and anxiety, and military-related issues including traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD), can conveniently access Nexalin's frequency-based neurostimulation treatment using the HALO headset from their residences. This innovative platform enables remote treatment oversight, safeguards patient privacy, and guarantees uninterrupted care. It operates on a subscription model, ensuring both financial viability and improved long-term health outcomes for patients.
Patients can commence their treatment journey remotely, circumventing the need for physical clinic visits. This eliminates waiting times, reduces physician overheads, and addresses the stigma often associated with seeking treatment by providing a discreet, home-based environment. Real-time monitoring tools further empower physicians to closely track patient progress. Previously, Nexalin Technology emphasized the robust peer-reviewed clinical research validating its neurostimulation technology across a spectrum of neurological and psychiatric conditions, reinforcing the efficacy and safety of its approach.
Nexalin Technology's stock experienced an upward trend, rising by 11.51% to $0.63 in premarket trading, as reported by Benzinga Pro data, following these significant developments.